ATG5 and head and neck squamous cell carcinoma: An unexpected finding that G2M checkpoint inhibitors may have a therapeutic effect on ATG5 high expression HNSCC and NPC, but more basic studies and clinical trials are still needed to validate the therapeutic effect.